Corporate Events

Otsuka Holdings Co., Ltd. declared dividend for the second quarter ended June 30, 2025 and revised dividend guidance for the fiscal year ending December 31, 2025. for the second quarter end, the company declared dividend of JPY 70.00 per share against JPY 60.00 per share a year ago. Scheduled date of dividend payment commencement: September 1, 2025. Record date is June 30, 2025. for the year end, the company expects dividend of JPY 70.00 per share against JPY 60.00 per share expected previously.

Otsuka Holdings Co., Ltd. revised consolidated financial forecast for the year ending December 31, 2025. For the year, the company expects revenue of ¥2,380,000 million, operating profit of ¥450,000 million, Profit for the year of ¥334,000 million, profit attributable to owners of the company of JPY 330,000 and Basic earnings per share of JPY 622.52 against revenue of ¥2,380,000 million, operating profit of ¥375,000 million, Profit for the year of ¥279,000 million, profit attributable to owners of the company of JPY 275,000 and Basic earnings per share of JPY 512.01 expected previously. In the pharmaceutical business, revenue is expected to exceed the segment forecast announced in February partly owing to the new consolidation of the U.S. IV solution business company Otsuka ICU Medical, despite the impact of exchange rates. In the nutraceutical business, revenue is expected to fall short of the February plan due to the impact of exchange rates. As a result, consolidated revenue is expected to be in line with the February plan. Selling general and administrative expenses are expected to be less than the February plan due to the impact of exchange rates. The Group will continue to engage in growth investment involving new businesses and promote further cost adjustments in existing businesses. Research and development expenses are expected to be lower than the planned amount due to the impact of foreign exchange fluctuations, despite planned investments toward sustainable growth, for the development of its "Next 8" products in the development pipeline such as the new antipsychotic agent ulotaront, and zipalertinib under development for the treatment of non- small cell lung cancer, as well as repinatrabit of Jnana acquired in the previous fiscal year. Business profit is expected to exceed the plan. This is because although revenue is expected to be in line with the plan, selling, general and administrative expenses and research and development expenses are expected to be less than the plan. Operating profit is also expected to exceed the plan. This is due to the increase in other income as a result of performing a series of accounting treatment related to the sale of some shares of MicroPort Scientific Corporation, which was an associate accounted for using the equity method. In line with this, profit before tax and profit attributable to owners of the Company are expected to exceed the target amoun ts. In addition, the situation is extremely opaque due to factors such as the impacts of pharmaceutical pricing policies and tariffs in the U.S. However, the Company is taking all possible measures and expects that such impacts on the operating results in 2025 will be limited.

Otsuka Holdings Co., Ltd. announced that the company have decided to increase annual dividend to JPY 140 per share in Fiscal Year 2025. They will continue to implement shareholder returns in line with the fourth midterm plan, while promoting flexible capital policies that respond to changes in the business environment from multiple perspective.

Otsuka Holdings Co., Ltd. revised consolidated financial forecast for the first half of Fiscal Year Ending December 31, 2025. For the six months, the company expects revenue of ¥1,180,000 million, operating profit of ¥242,00 million, Profit attributable to owners of parent of ¥173,000 million and Basic earnings per share of ¥325.12 against revenue of ¥1,174,000 million, operating profit of ¥200,00 million, Profit attributable to owners of parent of ¥147,000 million and Basic earnings per share of ¥276.26 previously announced.

Otsuka Holdings Co., Ltd., Board Meeting, Jul 31, 2025. Agenda: To consider Payment of Interim Dividend and Revision of Annual Dividend Forecast.

Otsuka Holdings Co., Ltd., Q2 2025 Earnings Call, Jul 31, 2025

To discuss Phase 3 Interim Analysis Results for sibeprenlimab at ERA

Otsuka Holdings Co., Ltd. Presents at European Renal Association 2025, Jun-10-2025 .

European Renal Association, European Renal Association 2025, Jun 10, 2025.

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co. Ltd. (Otsuka) presented results from a pre-specified interim analysis of the Phase 3 VISIONARY study (NCT05248646) evaluating sibeprenlimab, for the treatment of immunoglobulin A nephropathy (IgAN) in adults. Patients treated with sibeprenlimab achieved a 51.2% (P<0.0001) reduction in proteinuria (as measured by 24-hour uPCR [urine protein-to-creatinine ratio) at nine months of treatment when compared to placebo. The data were presented during a late-breaking clinical trials session at the European Renal Association (ERA) Congress in Vienna, Austria. The study, the Phase 3 IgAN trial conducted to date, also showed the safety profile of sibeprenlimab was favorable and consistent with previously reported data. Specifically, 76.3% of patients treated with sibepren Limab experienced any Treatment Emergent Adverse Event (TEAE) versus 84.5% in the placebo group.1 Patients who experienced a serious TEAE were 3.9% treated with sibeprenab compared to 5.4% treated with placebo. Sibeprenlimab received Priority Review designation from the FDA last month following its BLA filing in March. Proteinuria reduction is a recognized surrogate marker correlating with delaying progression to kidney failure and has been used as an endpoint in IgAN clinical trials to support accelerated. regulatory approvals. Sibeprenlimib is an investigational monoclonal antibody that selectively inhibits the activity of APRIL (A PRol proliferation-Inducing Ligand) in adults with IgAN. APRIL plays a key role in the 4-hit process of IgAN pathogenesis and is an important initiating and sustaining factor in IgAN progression by promoting the production of pathogenic Gd-IgA1 and immune complex formation. By selectively binding and inhibiting APRIL, sibeprenlimab reduces the amount of immunoglobulin A (IgA) and Gd-IgA 1 levels1. Lower levels of Gd-IgA2 in people with IgAN provide less substrate for immune complex formation7. Sibeprenlim AB is administered in a single-dose prefilled syringe for subcutaneous injection every four weeks intended for self-administration or administration by caregiver, providing patients the option of convenience at home. The VISIONARY study continues in a blinded manner to evaluate the change in kidney function over 24 months as measured by estimated glomerular filtration rate (eGFR) and is expected to be an effective and safe approach for this progressive and irreversible kidney disease. The VISIONARY study continue in a blinded manner to evaluate The change in kidney function over 24 weeks as measured by estimated glomerultration rate (eGR) and is expected to be in the U.S. Food and Drug Administration (FDA) with a target action date of November 28th, 2025.

Otsuka Holdings Co., Ltd. has completed a Fixed-Income Offering in the amount of ¥10 billion. Security Name: 2.016% Unsecured Straight Bonds due May 28, 2035 Security Type: Corporate Bond/Note (Non Convertible) Principal Amount: ¥10 billion Price\Range: 100% Security Features: Unsecured Coupon Type: Fixed

Otsuka Holdings Co., Ltd. has completed a Fixed-Income Offering in the amount of ¥10 billion. Security Name: 1.626% Unsecured Straight Bonds due May 28, 2032 Security Type: Corporate Bond/Note (Non Convertible) Principal Amount: ¥10 billion Price\Range: 100% Security Features: Unsecured Coupon Type: Fixed

Otsuka Holdings Co., Ltd. has completed a Fixed-Income Offering in the amount of ¥10 billion. Security Name: 1.332% Unsecured Straight Bonds due May 28, 2030 Security Type: Corporate Bond/Note (Non Convertible) Principal Amount: ¥10 billion Price\Range: 100% Security Features: Unsecured Coupon Type: Fixed

Otsuka Holdings Co., Ltd. has filed a Shelf Registration in the amount of ¥200 billion. Security Name: Bonds Principal Amount: ¥200 billion

Otsuka Holdings Co., Ltd. provided consolidated financial forecast for the six months of 2025 and Fiscal Year Ending December 31, 2025. For the six months, the company expects revenue of ¥1,174,000 million, operating profit of ¥200,00 million, Profit attributable to owners of parent of ¥147,000 million and Basic earnings per share of ¥276.26. For the year, the company expects net sales of ¥2,380,000 million, operating profit of ¥375,000 million, Profit attributable to owners of parent of ¥275,000 million and Basic earnings per share of ¥518.76.

Otsuka Holdings Co., Ltd. provided dividend forecast for the second quarter of 2025 and Fiscal Year Ending December 31, 2025. For the quarter, the company expects to pay a dividend of ¥60 per share against ¥60 per share a year ago. For the year, the company expects to pay a dividend of ¥60 per share against ¥60 per share a year ago.

Otsuka Holdings Co., Ltd. announced that they will report Q2, 2025 results at 1:30 PM, Tokyo Standard Time on Jul 31, 2025

Otsuka Holdings Co., Ltd. (TSE:4578) is considering options for its holding in Hong Kong-listed MicroPort Scientific Corporation (SEHK:853), including selling its stake in the medical device maker, according to people familiar with the situation. The Japanese drugmaker is working with an adviser on a review of its minority stake after receiving preliminary interest from prospective investors, the people said, asking not to be identified discussing a private matter.

A fund backed by Shanghai Industrial Investment (Holding) Co., Ltd. is in talks to buy Otsuka Holdings Co., Ltd. (TSE:4578)’s stake in Chinese medical device maker MicroPort Scientific Corporation (SEHK:853), according to people familiar with the situation. Otsuka has been considering options for its holding in Hong Kong-listed MicroPort, including selling it, Bloomberg News reported in October. The Japanese drugmaker’s stake was about 20.9% as of the end of June.

Otsuka Holdings Co., Ltd., Board Meeting, Apr 30, 2025. Agenda: To conduct a purchase and cancellation of treasury shares.

The company closed its plan on April 14, 2025.

From April 1, 2025 to April 14, 2025, the company has repurchased 1,525,000 shares, representing 0.28% for ¥10,993.13 million. With this, the company has completed the repurchase of 9,035,800 shares, representing 1.68% for ¥69,999.82 million under the buyback announced on March 18, 2025.

Otsuka Holdings Co., Ltd., Q1 2025 Earnings Call, Apr 30, 2025

Otsuka Holdings Co., Ltd., ¥ 60.0, Cash Dividend, Jun-27-2025

Otsuka Holdings Co., Ltd. expected to report First-Half, 2025 results on July 29, 2025. This event was calculated by S&P Global (Created on April 4, 2025).

From March 18, 2025 to March 31, 2025, the company has repurchased 7,510,800 shares, representing 1.4% for ¥59,006.68 million. With this, the company has completed the repurchase of 7,510,800 shares, representing 1.4% for ¥59,006.68 million under the buyback announced on March 18, 2025.

Otsuka Pharmaceutical Co. Ltd. (Otsuka) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announced the filing of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for sibeprenlimab, an investigational monoclonal antibody that selectively inhibits the activity of APRIL (A PRoliferation-Inducing Ligand) in adults with immunoglobulin A nephropathy (IgAN). APRIL plays a key role in the 4-hit process of IgAN pathogenesis and is an important initiating and sustaining factor in IgAN progression by promoting the production of pathogenic Gd-IgA1 and immune complex formation. Sibeprenlimab is a single-dose prefilled syringe for subcutaneous injection every four weeks intended for self-administration or administration by caregiver, providing patients the option of convenience at home. IgAN is a progressive, autoimmune, chronic kidney disease that is associated with a high risk for progression to end-stage kidney disease (ESKD) over the lifetime of many patients. In 2024, the FDA granted a Breakthrough Therapy designation for sibeprenlimab following favorable results of the Phase 2 ENVISION clinical trial. This designation accelerates the development and regulatory review of potential new medicines intended to treat a serious condition and address a significant unmet medical need. If approved, sibeprenlimab would be administered via injection every four weeks, which would allow patients the convenience and option of self-administration in the home setting. The BLA submission, Otsuka's first, is supported by results from the Phase 2 ENVISION clinical trial (NCT04287985) and the Phase 3 VISIONARY clinical trial (NCT05248646), which met its primary endpoint by demonstrating that sibeprenlimab produced a statistically significant and clinically meaningful reduction in 24-hour uPCR (urine protein-to-creatine ratio) compared to placebo after nine months of treatment.4 In the trial, the safety profile of sibeprenlimab was favorable and consistent with previously reported data. The VISIONARY study is a multicenter, randomized, double-blind, placebo-controlled trial consisting of approximately 530 adult patients (largest trial to date) with IgA nephropathy who were receiving standard-of-care therapy (defined as maximally tolerated ACE inhibitor or ARB +/- SGLT2 inhibitor), designed to evaluate the efficacy and safety of sibeprenlimab 400 mg administered subcutaneously every four weeks, compared to placebo. The primary efficacy endpoint is to evaluate the change in 24-hour uPCR at 9 months compared with baseline. The secondary endpoint is to evaluate the annualized slope of eGFR estimated over 24 months.

Otsuka Holdings Co., Ltd., Board Meeting, Mar 28, 2025. Agenda: To implement the disposal of treasury shares; and to consider other business matters.

Annual Shareholders Meeting

Otsuka Holdings Co., Ltd. (TSE:4578) announces a share repurchase program. Under the program, the company will repurchase up to 12,000,000 shares, representing 2.23% of its share capital, for ¥70,000 million. The purpose of the program is to improve capital efficiency and return profits to shareholders. The program will expire on April 30, 2025. As of February 28, 2025, the company had 537,092,696 shares in issue (excluding treasury stock) and 14,932,021 shares in treasury.

The Board of Directors of Otsuka Holdings Co., Ltd. has authorized a buyback plan on March 18, 2025.

Otsuka Holdings Co., Ltd., Board Meeting, Mar 18, 2025. Agenda: To consider and approve repurchase its own shares pursuant to Article 459, Paragraph 1 of the Companies Act of Japan and to cancel its own shares pursuant to Article 178 of the same act.

Otsuka Holdings Co., Ltd. provided consolidated earnings guidance for the second quarter-end and year-end of the year ending December 31, 2025. For the second quarter-end, the company expects revenue to be JPY 1,174,000 million. Operating profit to be JPY 200,000 million. Profit attributable to owners of the Company to be JPY 147,000 million. Basic earnings per share to be JPY 273.69. For the year-end, the company expects revenue to be JPY 2,380,000 million. Operating profit to be JPY 375,000 million. Profit attributable to owners of the Company to be JPY 275,000 million. Basic earnings per share to be JPY 512.01.

Otsuka Holdings Co., Ltd. announced dividend of JPY 60.00 per share for the year ending December 31, 2024 against JPY 60.00 per share a year ago. Scheduled date of dividend payment commencement is March 31, 2025. The provided second quarter-end and year-end dividend guidance of the year ending December 31, 2025. For the second quarter-end, the company expects to pay dividend of JPY 60.00 per share against JPY 60.00 per share a year ago. For the year-end, the company expects to pay dividend of JPY 60.00 per share against JPY 60.00 per share a year ago.

Otsuka Holdings Co., Ltd. announced that they will report Q1, 2025 results at 1:30 PM, Tokyo Standard Time on Apr 30, 2025

Otsuka Holdings Co., Ltd., Annual General Meeting, Mar 28, 2025, at 10:00 Tokyo Standard Time. Agenda: To consider Business Report and Consolidated Financial Statements, as well as the audit reports of the Accounting Auditors and the Audit & Supervisory Board for Consolidated Financial Statements, for the 17th Fiscal Year (from January 1, 2024 to December 31, 2024); to consider Financial Statements for the 17th Fiscal Year (from January 1, 2024 to December 31, 2024); and to consider Election of Thirteen (13) Directors.

Otsuka Holdings Co., Ltd. expected to report Q1 2025 results on May 12, 2025. This event was calculated by S&P Global (Created on February 14, 2025).

Otsuka Holdings Co., Ltd. Presents at Autoimmunity Pharma & Biotech Partnering Summit, Nov-12-2024 09:00 AM. Venue: The Westin Boston Seaport District, 425 Summer Street, Boston, Massachusetts, United States. Speakers: Jonathan Zombeck, Director Business Development, Julien Genovino, Associate Director, Global Business Development & Strategy.

Otsuka Holdings Co., Ltd. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-15-2025 . Venue: The Westin St. Francis Hotel, San Francisco, California, United States.

Otsuka Holdings Co., Ltd. has completed a Fixed-Income Offering in the amount of ¥10 billion. Security Name: 0.911% Unsecured Straight Bonds due September 19, 2031 Security Type: Corporate Bond/Note (Non Convertible) Principal Amount: ¥10 billion Price\Range: 100% Security Features: Climate Bonds/Green Bonds; Unsecured Coupon Type: Fixed

Otsuka Holdings Co., Ltd. has completed a Fixed-Income Offering in the amount of ¥10 billion. Security Name: 1.219% Unsecured Straight Bonds due September 20, 2034 Security Type: Corporate Bond/Note (Non Convertible) Principal Amount: ¥10 billion Price\Range: 100% Security Features: Climate Bonds/Green Bonds; Unsecured Coupon Type: Fixed

Otsuka Holdings Co., Ltd., 2024 Earnings Call, Feb 14, 2025

Otsuka Holdings Co., Ltd. Presents at 8th Annual Neuroscience Innovation Forum, Jan-12-2025 . Venue: Marines’ Memorial Club, San Fracisco, California, United States.

The company closed its plan on November 22, 2024.

From October 1, 2024 to November 22, 2024, the company has repurchased 3,334,000 shares, representing 0.62% for ¥29,846.32 million. With this, the company has completed the repurchase of 5,810,900 shares, representing 1.07% for ¥49,882.99 million under the buyback announced on August 1, 2024.

Otsuka Holdings Co., Ltd. announced the changes of CEO. Changes of Directors: Name: Tatsuo Higuchi. Current Position: President and Representative Director, CEO. New Position: Executive Director and Advisor. Effective Date is January 1, 2025. Name: Makoto Inoue; Current Position: Representative Director, COO; New Position: CEO; Effective Date: January 1, 2025.

Otsuka Holdings Co., Ltd., Board Meeting, Oct 31, 2024. Agenda: To consider the changes of representative director.

Otsuka Holdings Co., Ltd. announced that they will report fiscal year 2024 results at 1:30 PM, Tokyo Standard Time on Feb 14, 2025

Otsuka Holdings Co., Ltd. has announced a Fixed-Income Offering. Security Name: 1.219% Unsecured Straight Bonds due September 20, 2034 Security Type: Corporate Bond/Note (Non Convertible) Principal Amount: ¥10 billion Security Features: Climate Bonds/Green Bonds; Unsecured Coupon Type: Fixed

Otsuka Holdings Co., Ltd. has announced a Fixed-Income Offering. Security Name: 0.911% Bonds Security Type: Corporate Bond/Note (Non Convertible) Principal Amount: ¥10 billion Coupon Type: Fixed

Otsuka Holdings Co., Ltd. expected to report Fiscal Year 2024 results on February 10, 2025. This event was calculated by S&P Global (Created on October 14, 2024).

Otsuka Holdings Co., Ltd., Q3 2024 Earnings Call, Oct 31, 2024

From July 31, 2024 to September 30, 2024, the company has repurchased 2,476,900 shares, representing 0.46% for ¥20,036.67 million. With this, the company has completed the repurchase of 2,476,900 shares, representing 0.46% for ¥20,036.67 million under the buyback announced on August 1, 2024.